Bright Minds Biosciences (Bright Minds Biosciences) Common Stock : $26.12 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Common Stock?

Bright Minds Biosciences's quarterly common stock declined from Jun. 2023 ($25.53 Mil) to Sep. 2023 ($25.06 Mil) but then increased from Sep. 2023 ($25.06 Mil) to Dec. 2023 ($26.12 Mil).

Bright Minds Biosciences's annual common stock increased from Sep. 2021 ($21.37 Mil) to Sep. 2022 ($24.17 Mil) and increased from Sep. 2022 ($24.17 Mil) to Sep. 2023 ($25.06 Mil).

Bright Minds Biosciences Common Stock Historical Data

The historical data trend for Bright Minds Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Common Stock Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Common Stock

0.74

21.37

24.17

25.06

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial												24.79	24.79	25.53	25.06	26.12

Bright Minds Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.